1 / 12

New Antiinflammatory Strategy to Treat Murine Dry-Eye Disease

New Antiinflammatory Strategy to Treat Murine Dry-Eye Disease. André Okanobo, MD, Mohammad Dastjerdi, MD, Sunil Chauhan, DVM, PhD, Nambi Nallasamy, BS, Zahra Sadrai, MD, Reza Dana, MD, MPH, MSc. Schepens Eye Research Institute, Harvard Medical School, Boston, MA

anthea
Télécharger la présentation

New Antiinflammatory Strategy to Treat Murine Dry-Eye Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Antiinflammatory Strategy to Treat Murine Dry-Eye Disease André Okanobo, MD, Mohammad Dastjerdi, MD, Sunil Chauhan, DVM, PhD, Nambi Nallasamy, BS, Zahra Sadrai, MD, Reza Dana, MD, MPH, MSc. Schepens Eye Research Institute, Harvard Medical School, Boston, MA Financial Disclosures :The Schepens Eye Research Institute and Mass. Eye and Ear Infirmary hold rights to the intellectual property for the use of IL-1 blockade in ocular surface disease. Financial support: Prevent Blindness America and NIH K24EY019098

  2. Inflammation and Dry Eye • Dry eye was originally considered to be simply a lack, or diminishment, of tear production • We now know that inflammation plays a critical role in the pathophysiology • This is supported by clinical data using anti-inflammatory therapies which lead to significant amelioration of the signs and symptoms of DED

  3. IL-1 and IL-1Receptor Are Upregulated in Dry Eye Normal IL-1R Expression; Cross-Section Cornea Epifluorescent Microscope AC AC AC Dry Eye EP EP 40x 40x 40x 40x

  4. Propose • Given that IL-1–mediated mechanisms play a critical role in corneal inflammation, we propose that local blockade of IL-1 may offer a novel approach to the management of dry eye disease

  5. Kinase, Phosphatase, etc. Signal Transduction Interleukin-1 (IL-1) Proinflammatory forms Anti-inflammatory form IL-1 receptor antagonist (IL-1Ra) • IL-1α • IL-1β IL-1R IL-1 IL-1R IL-1 IL-1AcP IL-1AcP IL-1Ra

  6. Induction of Dry Eye Disease • Controlled Environment Chamber • humidity below 25% • constant temperature of 21-23ºC • airflow of 15 L/minute • Topical atropine and SC scopolamine Barabino S, et al. The controlled environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46(8):2766-2771.

  7. Topical formulation and treatment regiment • Formulation prepared by MEEI pharmacy • Masked Fashion Control Environment Chamber Treatment Induction of Dry Eye DAY • Groups (n=6 eye) • IL-1Ra • CsA • Methylprednisolone • 4. Vehicle (1% carboxymethylcellulose) • 5. Untreated (no eye drops) 0 1 2 3 4 5 6 7 8 9 10 Euthanized CFS CFS CFS CFS 3µl (3x/day) CFS: Corneal Fluorescein Staining

  8. Corneal Staining

  9. mRNA expression levels of IL-1β in the cornea

  10. Enumeration of macrophages in the cornea

  11. IL-1Ra inhibits lymphangiogenesis in dry eye Dry Eye Normal IL-1Ra 5% LYVE-1(Lymphatics Vessels) / CD31(Blood Vessels)

  12. Conclusion • IL-1Ra ameliorates dry eye disease comparable to methylprednisolone • Signs: CFS scores were significantly improved • Our data suggests that this is due to the marked inhibition of corneal inflammation: • Down regulated levels of IL-1β mRNA • Reduced infiltration of macrophages • Inhibition of lymphangiogenesis • Thus the use of topical IL-1Ra appears to be a promising therapeutic modality to dry eye disease and possibly in other inflammatory conditions of the cornea and ocular surface

More Related